You're viewing a free preview.You're viewing a free preview — a sample of each dataset.
Regulatory
FDA, EMA and policy developments that move aging research and the longevity market.
158 regulatory items tracked
| Item | Category | Date |
|---|---|---|
| FDA 510(k) clearance for NeuroXT's NEXT-Cue AI software supporting prognostic assessment in mild cognitive impairment | FDA | 10/20/26 |
| FDA clears United Therapeutics' IND for the SUMMIT trial of treprostinil SMI in pulmonary hypertension associated with COPD | FDA | 10/19/26 |
| FDA leaders say aging and longevity are a priority at ARDD, with aging to feature in the next Focus Areas of Regulatory Science | FDA | 10/02/26 |
| FDA clears Surrozen's IND for SZN-8141, a Wnt-agonist and VEGF-blocking antibody for diabetic macular edema | FDA | 10/02/26 |
| FDA approves AbbVie's JUVMO (tavapadon) for Parkinson's disease | FDA | 09/28/26 |
| FDA clears C2N Diagnostics' PrecivityAD2, first Alzheimer's blood test for adults as young as 40 | Approval | 08/20/26 |
| Enveda reports positive Phase 1 results for ENV-308, first pill designed from the chemistry of exercise | Other | 08/18/26 |
| FDA grants accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg) plus nivolumab for advanced melanoma | FDA Approval | 08/06/26 |
| FDA approves mFLUSIVA (mRNA-1010), Moderna’s mRNA influenza vaccine for adults 50 and older | FDA Approval | 08/06/26 |
| FDA grants Fast Track designation to XellSmart's off-the-shelf iPSC cell therapy XS411 for Parkinson's disease | FDA | 08/04/26 |
Showing 10 of 158 regulatory items
7-day free trial · already have an account?
Peek at other modules
News Feed
Daily longevity science headlines — aging research, deals, trials, and policy — with AI summaries.
Companies
The longevity science company universe by segment, stage, geography and capital raised.
Funding Tracker
Every disclosed longevity science round — size, stage and the investors behind it.
Clinical Trials
Longevity science and aging research trials by phase, sponsor, status and indication.
People & Movers
Who is joining, leaving and founding across longevity science and aging research.
Research
Peer-reviewed aging research distilled into investor-relevant takeaways.